AzTrials
AzTrials

Infantile ColicNCT03877458

Combined Probiotics is More Effective in the Treatment of Infantile Colic

A study testing L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 and L. reuteri GL-104 in people with Infantile Colic, run by China Medical University Hospital at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longum and B. bifidum group, Lactobacillus reuteri or placebo group. Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Read more about this study

Who is it for?
Ages 3 weeks to 3 months
Conditions the study is for
Infantile Colic
What is being tested?
L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 and L. reuteri GL-104
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
99 participants
Where
1 siteTaiwan
Study dates
16 Feb 2017to 31 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 weeks to 3 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement.
  • Age 3 weeks to 3 months at study commencement.
  • Infants are born in full term (greater than 37 weeks) and the birth weight more than 2500 grams.

Who cannot join

  • A major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician.
  • History of antibiotic treatment before or during the study.
  • History of probiotic supplementation.
  • History of any allergies to any of the ingredients in the probiotic mixture of L. acidophilus, B. longum and B. bifidum or placebo.
  • Concurrent participation in another clinical trial.

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • China Medical University Hospital

    Taichung, 40447

Other trials in Taiwan

About this study

All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longum and B. bifidum group, Lactobacillus reuteri or placebo group.

Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6 months.

Read the detailed description

Infantile colic or excessive infant crying with no medical cause is a burdensome condition. Although crying is often considered "normal behavior," 5%-40% of infants cry inconsolably and excessively, accompanied by bouts of fussiness and gas passing.

The etiology of infantile colic remains unclear; various theories have been proposed, however, recent studies have implicated a potential role of the intestinal microbiome ,colicky infants presents lower amounts of Bifidobacteria and Lactobacilli. Several randomized clinical trials (RCT) have been conducted to examine the effectiveness of Lactobacillus reuteri DSM17938 vs placebo in the treatment of infantile colic. However, there is no trial adopt probiotics contained Bifidobacteria and Lactobacilli to treat infantile colic. In view of the above evidences, the investigators thus hypothesis that probiotics contained Bifidobacteria and Lactobacilli will more effect to increase the diversity of intestinal microbiome and alleviate infantile colic. The objective of this study is to evaluate the efficacy of combine probiotics (L. acidophilus, B. longus and B. bifidus) compare to Lactobacillus reuteri in the treatment infantile colic. Fecal calprotectin levels and microbial community in colic infants before and after probiotics will be evaluated to explore the mechanism of effectiveness of probiotics.

This, double-blind RCT will be carried out from December 2016 to November 2018 at Children's hospital of China Medical university. Eligible infants are included in the study after written informed consent is obtained from a parent/guardian. Study participants will meet the following inclusion criteria: (1) diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement; (2) age 3 weeks to 5 months at study commencement (although infantile colic typically manifests between age 2 weeks and 3-4 months, to capture infants with delayed onset of colic, infants with colic up to 6 months were eligible); (3) exclusively breastfed; (4) term delivery (≥37 weeks gestation); and (5) healthy infants with birth weight ≥2500 g. Exclusion criteria included: (1) a major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician; (2) history of antibiotic treatment before or during the study; (3) history of probiotic supplementation; (4) history of any allergies to any of the ingredients in the probiotic mixture of acidophilus, B longus and B. bifidus or placebo (sunflower oil, medium-chain triglyceride oil, and silicon dioxide); and (5) concurrent participation in another clinical trial.

Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6months.

All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longus and B. bifidus group, Lactobacillus reuteri or placebo group. Independent Research Support Pharmacy personnel, not participating in the study at the pharmacy of the Children Hospital prepare a computer-generated 3-treatment randomization schedule with a random block of varying size to ensure balance in the allocation of participants between treatment arms. Stool bacterial microbiota will be accessed by next generation sequence and fecal calprotectin will be measured by ELISA.

A minimum of 60 participants per study arm is needed to provide 80% power to detect an effect size of 0.5 and a detectable difference between groups in mean crying and fussing times of 50 minutes. Statistical analyses are performed using SPSS version 20 (IBM, Armonk, New York) using an intention-to-treat approach. The Student t test is used to compare mean values of continuous variables approximating a normal distribution, and the Mann-Whitney U test is used for nonnormally distributed variables. Proportions are compared using the χ2 test or Fisher exact test, as appropriate. All reported statistical tests are 2-sided.

Conditions
Infantile Colic
Being tested
L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088, L. reuteri GL-104, Placebo
Keywords
Infantile Colic, Bifidobacteria and Lactobacilli, Intestinal Microbiome, Probiotics
Medical subject headings
Colic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088Other

    Taking 1 mix probiotics capsule at bed time everyday for three months.

  • L. reuteri GL-104Other

    Taking 1 probiotic capsule at bed time everyday for three months.

  • PlaceboOther

    Taking 1 placebo capsule at bed time everyday for three months.

Study groups in NCT03877458
Study groupRoleWhat they receive
L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088ExperimentalTaking 1 mix probiotics capsule at bed time everyday for three months.
Receives: Other: L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088
L. reuteri GL-104ExperimentalTaking 1 probiotic capsule at bed time everyday for three months.
Receives: Other: L. reuteri GL-104
Placebo groupPlacebo comparatorTaking 1 Placebo capsule at bed time everyday for three months.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average crying and fussing times.

    Change in the duration of average crying and fussing times from baseline (day 0) to age 6 months, to <3 hours per day.

    Measured: 6 months.

Secondary outcomes (1)
  1. The number of participants.

    The number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6 months.

    Measured: 6 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2019
  2. Study start16 Feb 2017
  3. Primary completion11 Nov 2021
  4. Study completion31 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
99 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03877458
Sponsor's protocol ID
CMUH105-REC1-155
Status last verified
Mar 2023
First submitted
12 Mar 2019
Last updated
22 Mar 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 and L. reuteri GL-104 in people with Infantile Colic, run by China Medical University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average crying and fussing times. (time frame: 6 months.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in